Eslicarbazepine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Eslicarbazepine is an antiepileptic indicated as a monotherapy or adjunct therapy in the treatment of epilepsy.

Generic Name
Eslicarbazepine
DrugBank Accession Number
DB14575
Background

Eslicarbazepine is an anti-epileptic medication available commercially as eslicarbazepine acetate.

Type
Small Molecule
Groups
Approved
Structure
Weight
Average: 254.2839
Monoisotopic: 254.105527702
Chemical Formula
C15H14N2O2
Synonyms
  • Eslicarbazepina
  • Eslicarbazepine
  • S(+)-Liscarbazepine
External IDs
  • BIA 2-194
  • BIA-2-194
  • CGP-13751

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action

The precise mechanism(s) by which eslicarbazepine exerts anticonvulsant activity is unknown but is thought to involve inhibition of voltage-gated sodium channels.

TargetActionsOrganism
AP2X purinoceptor 4Not AvailableHumans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
1,2-BenzodiazepineThe risk or severity of CNS depression can be increased when 1,2-Benzodiazepine is combined with Eslicarbazepine.
AbemaciclibThe metabolism of Abemaciclib can be increased when combined with Eslicarbazepine.
AbrocitinibThe metabolism of Abrocitinib can be decreased when combined with Eslicarbazepine.
AcalabrutinibThe metabolism of Acalabrutinib can be increased when combined with Eslicarbazepine.
AcenocoumarolThe metabolism of Acenocoumarol can be increased when combined with Eslicarbazepine.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now

Categories

ATC Codes
N03AF04 — Eslicarbazepine
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as dibenzazepines. These are compounds with two benzene rings connected by an azepine ring. Azepine is an unsaturated seven-member heterocycle with one nitrogen atom replacing a carbon atom.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzazepines
Sub Class
Dibenzazepines
Direct Parent
Dibenzazepines
Alternative Parents
Azepines / Benzenoids / Ureas / Secondary alcohols / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Alcohol / Aromatic heteropolycyclic compound / Azacycle / Azepine / Benzenoid / Carbonic acid derivative / Carbonyl group / Dibenzazepine / Hydrocarbon derivative / Organic nitrogen compound
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
S5VXA428R4
CAS number
104746-04-5
InChI Key
BMPDWHIDQYTSHX-AWEZNQCLSA-N
InChI
InChI=1S/C15H14N2O2/c16-15(19)17-12-7-3-1-5-10(12)9-14(18)11-6-2-4-8-13(11)17/h1-8,14,18H,9H2,(H2,16,19)/t14-/m0/s1
IUPAC Name
(9S)-9-hydroxy-2-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3,5,7,12,14-hexaene-2-carboxamide
SMILES
NC(=O)N1C2=C(C[C@H](O)C3=C1C=CC=C3)C=CC=C2

References

General References
  1. FDA Approved Drug Products: Aptiom (eslicarbazepine acetate) tablets for oral use [Link]
  2. AIFA: ZEBINIX (eslicarbazepine) oral tablet [Link]
Human Metabolome Database
HMDB0060702
ChemSpider
8057180
RxNav
1482502
ChEBI
174358
ChEMBL
CHEMBL315985
ZINC
ZINC000000896938
Wikipedia
Eslicarbazepine_acetate

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentEpilepsy1
3CompletedTreatmentEpilepsy With Simple or Complex Partial Onset Seizures1
Not AvailableCompletedNot AvailableEpilepsy1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Tablet200 MG
Tablet800 MG
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.554 mg/mLALOGPS
logP1.26ALOGPS
logP1.73Chemaxon
logS-2.7ALOGPS
pKa (Strongest Acidic)14.1Chemaxon
pKa (Strongest Basic)-3.2Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count2Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area66.56 Å2Chemaxon
Rotatable Bond Count0Chemaxon
Refractivity72.29 m3·mol-1Chemaxon
Polarizability26.45 Å3Chemaxon
Number of Rings3Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-08fu-1790000000-a7f14b7ad0facf9f3f45
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-000l-0690000000-08d2f775039bf7fdff30
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-1940000000-87467905868d9c76e0a9
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0006-0920000000-ab04e9194362f2720286
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-9300000000-a36f3259aafad4f1e176
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-1900000000-a7701a079e18ffc2adae
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0006-0920000000-e7364a2d5a16325bebff
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-000l-0790000000-55467bf0ad4a41613ef2
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-000f-0960000000-fb0cd64293bec2770671
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0006-0920000000-ab5a571cd42d07c49c7c
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-9300000000-a36f3259aafad4f1e176
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-1900000000-41ef5625bf436bea155d
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0006-0910000000-39006c2ee96de203d153
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-163.3792793
predicted
DarkChem Lite v0.1.0
[M-H]-151.4616
predicted
DeepCCS 1.0 (2019)
[M-H]-163.3792793
predicted
DarkChem Lite v0.1.0
[M-H]-163.3792793
predicted
DarkChem Lite v0.1.0
[M-H]-151.4616
predicted
DeepCCS 1.0 (2019)
[M-H]-151.4616
predicted
DeepCCS 1.0 (2019)
[M+H]+164.1923793
predicted
DarkChem Lite v0.1.0
[M+H]+153.85716
predicted
DeepCCS 1.0 (2019)
[M+H]+164.1923793
predicted
DarkChem Lite v0.1.0
[M+H]+164.1923793
predicted
DarkChem Lite v0.1.0
[M+H]+153.85716
predicted
DeepCCS 1.0 (2019)
[M+H]+153.85716
predicted
DeepCCS 1.0 (2019)
[M+Na]+163.3143793
predicted
DarkChem Lite v0.1.0
[M+Na]+159.7697
predicted
DeepCCS 1.0 (2019)
[M+Na]+163.3143793
predicted
DarkChem Lite v0.1.0
[M+Na]+163.3143793
predicted
DarkChem Lite v0.1.0
[M+Na]+159.7697
predicted
DeepCCS 1.0 (2019)
[M+Na]+159.7697
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Yes
General Function
Zinc ion binding
Specific Function
Receptor for ATP that acts as a ligand-gated ion channel. This receptor is insensitive to the antagonists PPADS and suramin.
Gene Name
P2RX4
Uniprot ID
Q99571
Uniprot Name
P2X purinoceptor 4
Molecular Weight
43368.725 Da
References
  1. Tian M, Abdelrahman A, Weinhausen S, Hinz S, Weyer S, Dosa S, El-Tayeb A, Muller CE: Carbamazepine derivatives with P2X4 receptor-blocking activity. Bioorg Med Chem. 2014 Feb 1;22(3):1077-88. doi: 10.1016/j.bmc.2013.12.035. Epub 2013 Dec 25. [Article]

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
Curator comments
The FDA label reports a mild activation of UGT1A1- mediated glucuronidation was observed in human hepatic microsomes, in relation to eslicarbazepine metabolism.
General Function
Steroid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the...
Gene Name
UGT1A1
Uniprot ID
P22309
Uniprot Name
UDP-glucuronosyltransferase 1-1
Molecular Weight
59590.91 Da
References
  1. FDA Approved Drug Products: Aptiom (eslicarbazepine acetate) tablets for oral use [Link]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Bialer M, Soares-da-Silva P: Pharmacokinetics and drug interactions of eslicarbazepine acetate. Epilepsia. 2012 Jun;53(6):935-46. doi: 10.1111/j.1528-1167.2012.03519.x. Epub 2012 May 21. [Article]
  2. Bialer M, White HS: Key factors in the discovery and development of new antiepileptic drugs. Nat Rev Drug Discov. 2010 Jan;9(1):68-82. doi: 10.1038/nrd2997. [Article]
  3. Galiana GL, Gauthier AC, Mattson RH: Eslicarbazepine Acetate: A New Improvement on a Classic Drug Family for the Treatment of Partial-Onset Seizures. Drugs R D. 2017 Sep;17(3):329-339. doi: 10.1007/s40268-017-0197-5. [Article]
  4. Eslicarbazepine, PDR [Link]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. FDA Approved Drug Products: Aptiom (eslicarbazepine acetate) tablets for oral use [Link]

Drug created at July 20, 2018 21:43 / Updated at January 22, 2022 00:13